U.S. Top 10 Pharmaceutical Companies by Market Turnover

U.S.Top 10 Pharmaceutical Companies by Market Turnover

Based on U.S. pharmaceutical sales of major pharma companies, we have prepared following list of top 10 pharmaceutical companies in United States.

The list contains Europe and U.S. based companies, but revenues considered are strictly from only USA. To maintain the consistency of reporting, all revenue figures are converted in USD billion for this analysis.

  1. Pfizer Inc. : USD  25.32 Billion
  2. Johnson & Johnson : USD  23.28 Billion
  3. Roche Holding AG : USD 22.76 Billion
  4. AbbVie Inc. : USD 21.52 Billion
  5. Amgen : USD 18.28 Billion
  6. Novartis AG : USD  17.56 Billion
  7. Merck & Co., Inc. : USD 16.60 Billion
  8. Gilead Sciences, Inc. : USD 16.20 Billion
  9. Sanofi S.A : USD 13.15 Billion
  10. Bristol-Myers Squibb : USD 12.58 Billion

Top 10 U.S. Pharma Companies

1.Pfizer Inc

Pfizer Inc - Company Snapshot & SWOT Analysis

Pfizer's 2018 revenue from U.S market was $25.32 billion, a decrease of  -2.75%, compared to 2017. Pfizer Inc. registered highest revenue from USA market which accounted for 47.21% of its total sales in FY 2018.On various product fronts, industry-wide pricing challenges and generic competition are few of the challenges for company in U.S. market.


2.Johnson & Johnson

Johnson & Johnson - Company Snapshot & SWOT Analysis

Johnson & Johnson registered highest revenue from USA market at USD 23.28 billion (Pharma division) which is an increase of  +8.43%, compared to 2017. Sales by U.S. companies were $41.9 billion (in all franchise) in 2018, $39.9 billion in 2017 and $37.8 billion in 2016. This represents increases of 5.1% in 2018, 5.4% in 2017 and 6.0% in 2016.


3.Roche Holding AG

Roche Holding AG - Company Snapshot & SWOT Analysis

Roche Holding AG reported revenue of USD 22.76 billion for the FY 2018 from U.S. market which saw an increase of 13.35% compared to FY 2017. In the U.S., sales increase led by Ocrevus, Perjeta and Lucentis. Ocrevus sales were supported by continued strong new patient demand as well as follow-up treatments. 


4.AbbVie Inc.

AbbVie Inc - Company Snapshot & SWOT Analysis

AbbVie Inc. reported U.S. revenue of USD 21.52 billion for the FY 2018 which saw an increase of 17.9% compared to FY 2017. Company's global sales were impacted by the launch of several direct biosimilar drugs. These drugs are launched at much cheaper price anticipated by AbbVie resulting decline in sales in Europe and other international markets.


5.Amgen Inc.

Amgen Inc. - Company Snapshot & SWOT Analysis

Amgen's full year, U.S. revenue increased by 1.27 percent to $18.28 billion, from 2017. Company's product sales grew 8 percent globally. New and recently launched products including Repatha® (evolocumab), Prolia® (denosumab), KYPROLIS® (carfilzomib) and XGEVA® (denosumab) registered double-digit growth.


6.Novartis AG

Novartis AG - Company Snapshot & SWOT Analysis

Novartis AG reported revenue of USD 17.56 billion for the FY 2018 which saw an increase of 3.69% compared to FY 2017.Novartis has decided to shed its Alcon eye-care unit and U.S. generics pills business to focus on newer high-tech drugs.


7.Merck & Co., Inc.

Merck & Co., Inc - Company Snapshot & SWOT Analysis

Merck reported revenue of USD 16.60 billion for the FY 2018 which saw an increase of 4.76% compared to FY 2017. Company's overall revenue is expected to increase by 5.68% and reach USD 44.700 billion by FY 2019.Looking into 2019, Merck said it sees non-GAAP earnings of between $4.57 and $4.72 per share on worldwide sales of between $43.2 billion and $44.7 billion.


8.Gilead Sciences, Inc.

Gilead Sciences, Inc.- Company Snapshot & SWOT Analysis

Gilead Sciences, Inc. (Gilead) is a U.S. based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead’s primary areas of focus include HIV/AIDS, liver diseases, hematology/oncology and inflammation/respiratory diseases. Gilead reported revenue of USD 16.20 billion for the FY 2018 which saw decrease of 10.56% compared to FY 2017.


9.Sanofi S.A.

Sanofi S.A. - Company Snapshot & SWOT Analysis

Sanofi S.A. registered pharma revenue of USD 13.15 from USA market which is a decrease of  2.66%, compared to 2017. Although strong performances of Dupixent® and Aubagio®, together with the consolidation of Eloctate® and Alprolix® sales have partly offset the lower sales of the Diabetes franchise and of sevelamer.


10.Bristol-Myers Squibb Company

Bristol-Myers Squibb - Company Snapshot & SWOT Analysis

Bristol-Myers Squibb's revenue from U.S. market valued at USD 12.58 billion, which is a 11% higher than FY 2017. For 4th quarter U.S. revenues increased 16% to $3.3 billion in the quarter compared to the same period a year ago.

DISCLAIMER: * Rankings have been provided on the basis of pharma division revune, if you consider total revenue of a company rankings might change.
Global Pharmaceuticals Industry Analysis and Trends 2023

Global Pharmaceuticals Industry Analysis and Trends 2023: Report covers Competitive Landscape Of Global Pharma Companies


Browse Report

About The Author

Related Reports

Pharma Market Porter Five Forces
Pharma Market SWOT Analysis


Pharma Market Risk Analysis

Clients Who Trust Us

Need tailor made market research solution? We can help you with that too.

About Us

At Market Research Reports, Inc. we aim to make it easier for decision makers to find relevant information and locate right market research reports which can save their time and assist in what they do best, i.e. take time-critical decisions.

We work with our associate Global market research firms who are known leaders in their respective domains to obtain right market research solution for our customer’s needs, be it custom research or syndicated research reports.

Contact Us

Market Research Reports, Inc
16192 Coastal Hwy
, DE 19958, USA

USA: +1-302-703-9904

India: +91-8762746600



User login

Stay Connected